RELX PLC
No SEC Form 4 filings for $RELX in the last 30 days.
Global stocks edged lower as investors weighed slow progress on a potential US-Iran peace deal tied to reopening the Strait of Hormuz. In Dublin, Iseq rose 0.18%. Glanbia gained 5.61% after reporting 7% H1 2026 revenue growth. In London, FTSE 100 fell 0.19% and Diageo jumped 5.58% on a $1bn cost-cut plan. S&P 500 fell 0.24%.
Springer Nature and Relx reported “strong” first-half results. Springer Nature said underlying revenue rose 6.2% and adjusted operating profit rose 7.7% for the whole company, with research segment revenue up 7.2% and adjusted operating profit up 8.2%. Total revenue reached €940m and adjusted operating profit €246m, with research segment revenue €748m and €229m, according to the company.
LexisNexis Australia and the AustLII Foundation announced an agreement to support AustLII in developing AI-enhanced legal research tools for Australia’s free public legal information service. The companies said LexisNexis will accelerate AustLII’s AI capabilities using AustLII’s legal data collection. AustLII is hosted by UTS and is a not-for-profit.
Over the past 7 days, alphai's AI scored 2 news stories mentioning RELX (RELX PLC). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent RELX coverage spans earnings, financial news and macro economy.
Move appears macro-driven; no actionable RELX catalyst is disclosed.
Publishing-segment profit growth supports the earnings-quality narrative and may sustain positive sentiment toward RELX’s publishing cash flows.
The deal is a strategic partnership for AI-enabled legal research, but it does not disclose financial terms or measurable near-term revenue impact for RELX.
AI-enabled product adoption is positioned as the core driver of Relx’s improving growth and margin profile across STM and Legal divisions.
A reaffirmed Buy with a modest target increase is a mild positive signal, but it is not a new fundamental catalyst.
alphai scores every news story that mentions RELX with an AI model for sentiment and relevance, and aggregates insider trades from RELX PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Global stocks edged lower as investors weighed slow progress on a potential US-Iran peace deal tied to reopening the Strait of Hormuz. In Dublin, Iseq rose 0.18%. Glanbia gained 5.61% after reporting 7% H1 2026 revenue growth. In London, FTSE 100 fell 0.19% and Diageo jumped 5.58% on a $1bn cost-cut plan. S&P 500 fell 0.24%.
7 min readSpringer Nature and Relx reported “strong” first-half results. Springer Nature said underlying revenue rose 6.2% and adjusted operating profit rose 7.7% for the whole company, with research segment revenue up 7.2% and adjusted operating profit up 8.2%. Total revenue reached €940m and adjusted operating profit €246m, with research segment revenue €748m and €229m, according to the company.
2 min readLexisNexis Australia and the AustLII Foundation announced an agreement to support AustLII in developing AI-enhanced legal research tools for Australia’s free public legal information service. The companies said LexisNexis will accelerate AustLII’s AI capabilities using AustLII’s legal data collection. AustLII is hosted by UTS and is a not-for-profit.
3 min readRELX (RELX) reported H1 earnings call highlights, citing growth across Risk, STM, Legal, and Exhibitions. Risk and Insurance benefited from financial crime compliance and digital fraud solutions. STM revenue rose 6% and underlying adjusted operating profit 8%. Legal posted 10% underlying revenue growth and 13% profit growth, driven by Lexis+ with Protégé. Management reiterated full-year growth expectations and said AI token costs are under 1% of costs.
6 min readDeutsche Bank analyst Steve Liechti reaffirmed a Buy rating on RELX PLC and adjusted the target price from 3,050 to 3,100 GBX, according to MarketScreener. The article also notes UBS previously reiterated a Buy rating. RELX is described as an information and analytics provider across Risk & Business Analytics, Scientific, Technical & Medical, Legal, and Exhibitions.
2 min readRELX PLC reported strong first-half results, with group organic revenue up 7% and margins up 70 bps. UBS reiterated a buy and set a 3,600p target, while Deutsche Bank kept buy and raised its target to 3,100p. Analysts cited AI-led acceleration and no evidence of AI-related disruption, though an “AI overhang” may weigh near term.
5 min readAfter RELX PLC’s first-half results, Deutsche Bank kept a Buy rating and raised its target to 3,100p from 3,050p, while UBS reiterated Buy with a 3,600p target. UBS cited AI-led organic acceleration, with Scientific, Technical & Medical up to 6% and Legal to 10%, plus 7% organic revenue growth and 70 bps margin expansion. Analysts said AI disruption fears look overplayed but near-term sentiment may lag.
5 min readRELX plc (GB:REL) announced an irrevocable, non-discretionary share buyback to repurchase ordinary shares from 23 July to 4 September 2026, committing £150 million. The programme follows a completed £100 million buyback and is part of a wider £2.25 billion 2026 repurchase plan. Shares will be held in treasury, with total buybacks capped at 150.8 million shares, managed by ABN AMRO.
2 min readRELX PLC shares rose 1.5% to 2,491p after the FTSE 100 group reported higher first-half revenue and profit. Underlying revenue grew 7% and adjusted operating profit rose 9% to £1.7 billion, with margins improving to 35.5%. The board lifted the interim dividend 7% to 20.9p and said it expects strong full-year growth.
3 min readRelx shares rose about 2% in pre-open trading after the company reported H1 2026 interim results. According to Relx, underlying revenue grew 7% to £4,871m and adjusted operating profit rose 9% to £1,727m. Adjusted EPS increased 11% at constant currency, with Legal leading. Relx reaffirmed full-year outlook and said AI-enabled tools supported growth.
3 min read
